Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bendamustine + BEAM + autologous stem cell transplantation
- Development stage
- Unknown
- Lead developer
- Weill Cornell Medicine
- Modality
- Small Molecules, Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This therapeutic regimen, developed by Weill Medical College of Cornell University, is a sequential high-dose chemotherapy protocol followed by autologous stem cell transplantation (ASCT) for the treatment of refractory Hodgkin lymphoma and non-Hodgkin lymphoma. The regimen consists of an initial intensive phase using bendamustine, followed by the standard BEAM conditioning regimen, which includes carmustine, etoposide, cytarabine, and melphalan. Bendamustine serves as a bifunctional alkylating agent with antimetabolite properties, while the BEAM components provide multi-targeted cytotoxic action to eradicate residual malignant cells. Following this intensive conditioning, the patient's previously harvested hematopoietic stem cells are reinfused to restore bone marrow function. This sequential approach is specifically designed to improve complete response rates in patients who have failed standard salvage therapies.
- Other names
- B-BEAMBendamustine-BEAMSequential Bendamustine and BEAM conditioning
Beyond the preview
Go deeper on bendamustine + BEAM + autologous stem cell transplantation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bendamustine + BEAM + autologous stem cell transplantation.